Immunoglobulin M Efficacy AgainstCryptococcus neoformans: Mechanism, Dose Dependence, and Prozone-Like Effects in Passive Protection Experiments
Open Access
- 1 February 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 166 (3) , 2100-2107
- https://doi.org/10.4049/jimmunol.166.3.2100
Abstract
The IgM mAbs 12A1 and 13F1 are protective and nonprotective, respectively, against lethal Cryptococcus neoformans infection in mice. To better understand the variables that contribute to IgM efficacy against C. neoformans, we studied the effects of inoculum size, route of infection, and Ab dose for each of these mAbs. mAb 13F1 did not prolong survival under any condition studied. mAb 12A1 prolonged survival after the administration of certain Ab doses after i.p. infection with defined inocula and promoted phagocytosis, agglutination, and the formation of inflammatory cell rings around yeast cells in vivo. Large Ab doses of mAb 12A1 resulted in either no protection or enhanced infection, consistent with a prozone-like effect. Investigation of this phenomenon revealed that the fungal cell was protected against microbicidal nitrogen-derived oxidants when large amounts of Ab were bound to the C. neoformans capsule. mAb 12A1 was opsonic in vitro for peritoneal, but not splenic or alveolar macrophages. In summary, our results indicate that IgM efficacy against C. neoformans is a function of the route of infection, inoculum, and Ab dose and is associated with its ability to promote opsonization, agglutination, and phagocytic ring formation in vivo. The occurrence of the prozone-like phenomenon implies that high Ab titers are not necessarily beneficial in assuring protection against certain pathogens and that caution should be exercised in using high Ab titer as a measure for vaccine efficacy.Keywords
This publication has 56 references indexed in Scilit:
- Role of nitric oxide synthesis in macrophage antimicrobial activityPublished by Elsevier ,2003
- Quantitative and Qualitative Differences in the Serum Antibody Profiles of Human Immunodeficiency Virus–Infected Persons with and withoutCryptococcus neoformansMeningitisThe Journal of Infectious Diseases, 1999
- Monoclonal Antibody–Mediated Toxicity inCryptococcus neoformansInfection: Mechanism and Relationship to Antibody IsotypeThe Journal of Infectious Diseases, 1999
- Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release 1Medical Mycology, 1999
- Cryptococcus neoformans: Paradigm for the Role of Antibody Immunity Against Fungi?Zentralblatt für Bakteriologie, 1996
- Peptide Libraries Define the Fine Specificity of Anti-polysaccharide Antibodies toCryptococcus neoformansJournal of Molecular Biology, 1996
- J774 Murine Macrophage-like Cell Interactions with Cryptococcus neoformans in the Presence and Absence of OpsoninsThe Journal of Infectious Diseases, 1996
- Antibodies Elicited by a Cryptococcus neoformans-Tetanus Toxoid Conjugate Vaccine Have the Same Specificity as Those Elicited in InfectionThe Journal of Infectious Diseases, 1992
- An ultrastructural examination of the interaction between macrophages andCryptococcus neoformansThe Journal of Pathology, 1978
- The Units of Protective Antibody in Anti-Pneumococcus Serum and Antibody SolutionThe Journal of Infectious Diseases, 1928